Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR(r) in Canada

Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients

Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients

U.S. District Court Rules in Veloxis Litigation

Warrant Programme – Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

Veloxis Pharmaceuticals announces financial results for the first three months of 2015